In 2003, the company filed INDs for Numax(TM), a potential next-generation antibody targeting respiratory syncytial virus; an anti-IL-9 antibody targeting asthma; and siplizumab, an antibody targeting CD2 for T-cell lymphoma.
This patent rights agreement follows licenses granted to MedImmune in 1997 under Protein Design's antibody humanization patents for Synagis (palivizumab), the first monoclonal antibody approved to prevent an infectious disease, and for siplizumab, an antibody currently in Phase II testing as a treatment for psoriasis.
Revamped AlloMune System Development Strategy: The company revised its clinical development strategy for the AlloMune System and will now employ kits consisting of BioTransplant's proprietary antibody MEDI-507, also known as siplizumab, in combination with products that have already been approved in the United States.
Revamped AlloMune Development Strategy: BioTransplant is revising its clinical development strategy for the AlloMune System, employing kits consisting of siplizumab in combination with products that have already been approved in the United States.
This news release contains forward-looking statements about BioTransplant that involve risks and uncertainties, including, without limitation, statements relating to the implementation of the Company's restructuring plan, the filing of the Company's IND for siplizumab and the related patient enrollment, the commencement and completion of enrollment in the Massachusetts General Hospital study and the availability of cash.
In our other clinical programs, we see increasing support for the use of our Eligix(TM) HDM Cell Separation System, and we expect further results from MedImmune's Phase II trials of our siplizumab monoclonal antibody product in psoriasis patients in the third quarter this year.